By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Abbott today reported that its molecular diagnostics sales for the first quarter of 2011 grew around 14 percent year over year.

The Abbott Park, Ill.-based maker of medical diagnostics and devices, pharmaceuticals, and nutritional products, said that its molecular diagnostics products brought in revenue of $99 million for the quarter. Of that total, $45 million came from the US market and the rest from international markets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.